Cash/Burn From SEC Filing For Period: 

Q1 '20

NKTR

Nektar Therapeutics

We are a clinical-stage biopharmaceutical company with a proven track record of discovering and developing new medicines that treat patients living with debilitating diseases and conditions. We build on a chemistry platform that was invented in our labs along with our scientific expertise to focus on developing unique and more precise medicines.

Cash

$1.34B

Burn Rate

-$138.7M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Dapirolizumab Pegol

Systemic lupus erythematosus (SLE)

Phase 3

Q4 2020

NKTR 214 + Opdivo

Melanoma

Phase 3 (Data)

Data

Bempegaldesleukin + OPDIVO

Muscle-invasive Bladder Cancer

Phase 3 TBD

TBD

Bempegaldesleukin + OPDIVO

Renal Cell Carcinoma

Phase 3 TBD

TBD

Bempegaldesleukin + OPDIVO

Immuno-oncology

Phase 2

TBD

Bempegaldesleukin + OPDIVO (PIVOT 10 Study)

Urothelial Cancer

Phase 2 TBD

TBD

NKTR-358

Systemic Lupus Erythematosus.

Phase 1b (EULAR report-out)

Jun 05, 2020

Bempegaldesleukin+ KEYTRUDA® (pembrolizumab) (PROPEL)

Non-Small Cell Lung Cancer (NSCLC)

Phase 1 (Data)

Q4 2020

NKTR-255 + Daratumumab

Multiple Myeloma/Non Hodgkin Lymphoma

Phase 1 (Data)

Q4 2020

Bempegaldesleukin + VB10.NEO

Squamous Cell Carcinoma of the Head and Neck

Phase 1/2a

TBD

Onzeald (etirinotecan pegol)

Advanced Breast Cancer and Brain Metastases

Discontinued

Discontinued

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon